Glucagon-Like Peptide-1 and its Cardiovascular Effects

被引：0
作者：
Kyung-Sun Heo
Keigi Fujiwara
Jun-ichi Abe
机构：
[1] University of Rochester School of Medicine and Dentistry,Aab Cardiovascular Research Institute
来源：
Current Atherosclerosis Reports | 2012年 / 14卷
关键词：
Cardiovascular disease; Dipeptidyl peptidase-4; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Incretins; Myocardial infarction; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recently, the crucial role of GLP-1 in cardiovascular disease has been suggested by both preclinical and clinical studies. In vivo and in vitro studies have demonstrated cardio-protective effects of GLP-1 by activating cell survival signal pathways, which have greatly reduced ischemia/reperfusion injury and also cardiac dysfunction in various congestive heart failure animal models. Clinically, beneficial effects of GLP-1 have been shown in patients with myocardial infarction, hypertension, and heart failure, and 2 classes of incretin enhancers, GLP-1 receptor agonists and DPP-4 inhibitors, are currently available for the treatment of type 2 diabetes mellitus. In this review, we will summarize the role of incretins in various cardiovascular events such as hypertension and heart failure and postprandial lipoprotein secretion, and discuss their molecular mechanisms and potentials as a new therapeutic as well as preventive drug type for reducing cardiovascular events in both diabetic and nondiabetic patients.
引用
收藏
页码：422 / 428
页数：6
相关论文
共 283 条
[1]  
Sokos GG(2007)Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting Am J Cardiol 100 824-829
[2]  
Bolukoglu H(2006)Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 694-699
[3]  
German J(2005)Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 146-151
[4]  
Hentosz T(2010)Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction Resuscitation 81 755-760
[5]  
Magovern GJ(2003)Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2242-2252
[6]  
Maher TD(2005)Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines J Pharmacol Exp Ther 312 303-308
[7]  
Sokos GG(2009)Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157 1340-1351
[8]  
Nikolaidis LA(2007)Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131-2157
[9]  
Mankad S(1975)Identification and actions of gastric inhibitory polypeptide Recent Prog Horm Res 31 487-532
[10]  
Elahi D(1987)Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas J Clin Invest 79 616-619
12345678910